Literature DB >> 1759991

Chemotaxis of the monocyte cell line U937: dependence on cholesterol and early mevalonate pathway products.

J Kreuzer1, J Bader, L Jahn, M Hautmann, W Kübler, E Von Hodenberg.   

Abstract

In the present study we investigated the influence of cholesterol depletion and hydroxymethylglutaryl-coenzyme A reductase (HMG-CoA reductase) inhibition on chemotaxis of the human monocytic cell line U937. Chemotaxis was nearly completely depressed after incubation for 24 h in the absence of lipoproteins. This was accompanied by a significant decrease in cellular cholesterol. Addition of 10 micrograms/ml low density lipoprotein (LDL) for 2 h to the cholesterol-depleted cells restored chemotaxis. Free cholesterol had no effect under these conditions. Inhibition of HMG-CoA reductase by pravastatin (0.01-1.0 mM) for 20 or 72 h also reduced chemotaxis. However, this effect was not accompanied by a decrease in cellular cholesterol when cells were grown in the presence of lipoproteins. The effect of pravastatin could be reversed by the addition of mevalonate. Addition of LDL did not change the response to pravastatin. We propose that the availability of cholesterol plays an important role in cellular chemotaxis. Furthermore, it can be suggested that other products of the mevalonate pathway apart from cholesterol may contribute to the regulation of chemotaxis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1759991     DOI: 10.1016/0021-9150(91)90116-k

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  8 in total

Review 1.  Antiinflammatory and immunomodulatory properties of statins.

Authors:  Ora Shovman; Yair Levy; Boris Gilburd; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  Time-dependent degenerative transformations in the lipidome of chalazia.

Authors:  Jadwiga C Wojtowicz; Igor A Butovich; Anne McMahon; Robert N Hogan; Kamel M Itani; Ronald Mancini; Mike Molai; Emily Linsenbardt
Journal:  Exp Eye Res       Date:  2014-08-19       Impact factor: 3.467

Review 3.  Are there potential non-lipid-lowering uses of statins?

Authors:  D C Wheeler
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

Review 4.  The challenge of rejection and cardiac allograft vasculopathy.

Authors:  W G Cotts; M R Johnson
Journal:  Heart Fail Rev       Date:  2001-09       Impact factor: 4.214

Review 5.  The metabolic effects of cyclosporin and tacrolimus.

Authors:  P Marchetti; R Navalesi
Journal:  J Endocrinol Invest       Date:  2000 Jul-Aug       Impact factor: 4.256

6.  Lovastatin increases arachidonic acid levels and stimulates thromboxane synthesis in human liver and monocytic cell lines.

Authors:  N Hrboticky; L Tang; B Zimmer; I Lux; P C Weber
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

Review 7.  Do pleiotropic effects of statins beyond lipid alterations exist in vivo? What are they and how do they differ between statins?

Authors:  A Faggiotto; R Paoletti
Journal:  Curr Atheroscler Rep       Date:  2000-01       Impact factor: 5.967

Review 8.  Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa.

Authors:  Todd W Rice
Journal:  Vasc Health Risk Manag       Date:  2006
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.